Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey

BACKGROUND: The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who received at least three prior lines of therapy, including proteasome inhibitor and immunomodulatory agent. A retrospective multic...

Descripción completa

Detalles Bibliográficos
Autores principales: Markovic, Uros, Romano, Alessandra, Del Fabro, Vittorio, Bellofiore, Claudia, Bulla, Anna, Parisi, Marina Silvia, Leotta, Salvatore, Gentile, Massimo, Cangialosi, Clotilde, Vincelli, Iolanda, Mineo, Giuseppe, Rossi, Marco, Poidomani, Massimo, Uccello, Giuseppina, Maugeri, Cinzia, Mannina, Donato, Innao, Vanessa, Di Raimondo, Francesco, Conticello, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982826/
https://www.ncbi.nlm.nih.gov/pubmed/33763359
http://dx.doi.org/10.3389/fonc.2021.624405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982826/
https://www.ncbi.nlm.nih.gov/pubmed/33763359
http://dx.doi.org/10.3389/fonc.2021.624405

Ejemplares similares